Buil JB - Search Results

1

Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis¹.

Janssen NAF, Nyga R, Vanderbeke L, Jacobs C, Ergün M, Buil JB, van Dijk K, Altenburg J, Bouman CSC, van der Spoel HI, Rijnders BJA, Dunbar A, Schouten JA, Lagrou K, Bourgeois M, Reynders M, van Regenmortel N, Rutsaert L, Lormans P, Feys S, Debavaye Y, Tamion F, Costa D, Maizel J, Dupont H, Chouaki T, Nseir S, Sendid B, Brüggemann RJM, van de Veerdonk FL, Wauters J, Verweij PE. Janssen NAF, et al. Among authors: buil jb. Emerg Infect Dis. 2021 Nov;27(11):2892-2898. doi: 10.3201/eid2711.211174. Epub 2021 Sep 14. Emerg Infect Dis. 2021. PMID: 34519638 Free PMC article.

2

Are the TR46/Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?

Buil JB, Meis JF, Melchers WJ, Verweij PE. Buil JB, et al. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3259-60. doi: 10.1128/AAC.00256-16. Print 2016 May. Antimicrob Agents Chemother. 2016. PMID: 27107104 Free PMC article. No abstract available.

3

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE. Buil JB, et al. J Antimicrob Chemother. 2018 Jan 1;73(1):134-142. doi: 10.1093/jac/dkx354. J Antimicrob Chemother. 2018. PMID: 29048485

4

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE. Buil JB, et al. J Antimicrob Chemother. 2018 Jan 1;73(1):263. doi: 10.1093/jac/dkx425. J Antimicrob Chemother. 2018. PMID: 29112717 No abstract available.

5

Molecular Detection of Azole-Resistant Aspergillus fumigatus in Clinical Samples.

Buil JB, Zoll J, Verweij PE, Melchers WJG. Buil JB, et al. Front Microbiol. 2018 Mar 21;9:515. doi: 10.3389/fmicb.2018.00515. eCollection 2018. Front Microbiol. 2018. PMID: 29619020 Free PMC article. Review.

6

Trends in Azole Resistance in Aspergillus fumigatus, the Netherlands, 1994-2016.

Buil JB, Snelders E, Denardi LB, Melchers WJG, Verweij PE. Buil JB, et al. Emerg Infect Dis. 2019 Jan;25(1):176-178. doi: 10.3201/eid2501.171925. Emerg Infect Dis. 2019. PMID: 30561296 Free PMC article.

7

The fading boundaries between patient and environmental routes of triazole resistance selection in Aspergillus fumigatus.

Buil JB, Hare RK, Zwaan BJ, Arendrup MC, Melchers WJG, Verweij PE. Buil JB, et al. PLoS Pathog. 2019 Aug 22;15(8):e1007858. doi: 10.1371/journal.ppat.1007858. eCollection 2019 Aug. PLoS Pathog. 2019. PMID: 31437247 Free PMC article. No abstract available.

8

High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Schauwvlieghe AFAD, Buil JB, Verweij PE, Hoek RAS, Cornelissen JJ, Blijlevens NMA, Henriet SSV, Rijnders BJA, Brüggemann RJM. Schauwvlieghe AFAD, et al. Among authors: buil jb. Mycoses. 2020 Feb;63(2):122-130. doi: 10.1111/myc.13028. Epub 2019 Dec 15. Mycoses. 2020. PMID: 31660650 Free PMC article.

9

Burden of serious fungal infections in the Netherlands.

Buil JB, Meijer EFJ, Denning DW, Verweij PE, Meis JF. Buil JB, et al. Mycoses. 2020 Jun;63(6):625-631. doi: 10.1111/myc.13089. Epub 2020 Apr 28. Mycoses. 2020. PMID: 32297377 Free PMC article.

10

Pharmacokinetics and Pharmacodynamics of Posaconazole.

Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Chen L, et al. Among authors: buil jb. Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y. Drugs. 2020. PMID: 32323222 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page